Long-term outcomes and prognostic factors of high-risk malignant melanoma patients after surgery and adjuvant high-dose interferon treatment: A single-center experience

Chemotherapy

Volumn 60, Issue 4, 2014, Pages 228-238

  Akman, Tulay ^a   Oztop, Ilhan ^a   Unek, Ilkay Tugba ^a   Koca, Dogan ^d   Unal, Olcun Umit ^e   Salman, Tarik ^b   Yavuzsen, Tugba ^a   Yilmaz, Ahmet Ugur ^c   Somali, Isil ^a   Demir, Necla ^a   Ellidokuz, Hulya ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Clinic of Cardiology   (Turkey)

^d Istanbul Hospital   (Turkey)

^e ATATÜRK UNIVERSITY   (Turkey)

Author keywords

Clinicopathological features; Interferon; Melanoma; Prognostic factors; Survival; Treatment

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; INTERFERON;

ADULT; ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HIGH RISK PATIENT; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; SKIN METASTASIS; SUBCLINICAL HYPERTHYROIDISM; SUBCLINICAL HYPOTHYROIDISM; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THYROID DISEASE; THYROID FUNCTION TEST; ULCER; VOMITING; ADJUVANT CHEMOTHERAPY; AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SKIN NEOPLASMS; TIME; TREATMENT OUTCOME; TRENDS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERFERONS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929946426     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000371838     Document Type: Article

References (60)

1. Weinstock MA: Issues in the epidemiology of melanoma. Hematol Oncol Clin North Am 1998; 12: 681-698.
2. Berwick M, Halpern A: Melanoma epidemiology. Curr Opin Oncol 1997; 9: 178-182.
3. Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC: Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Chemotherapy 2009; 55: 221-227.
4. Hofmann MA, Gabriel V, Milling A, Kiecker F, Sterry W, Trefzer U: High-dose platinum combination therapy in pretreated patients with disseminated melanoma. Chemotherapy 2007; 53: 422-428.
5. Rigel DS, Russak J, Friedman R: The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010; 60: 301-316.
6. Kelly JW, Blois MS, Sagebiel RW: Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol 1985; 13: 756-760.
7. McCarthy WH, Shaw HM, Thompson JF, Milton GW: Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988; 166: 497-502.
8. Slingluff CL Jr, Dodge RK, Stanley WE, Seigler HF: The annual risk of melanoma progression: implications for the concept of cure. Cancer 1992; 70: 1917-1927.
9. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, Mc-Masters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
10. American Cancer Society: Cancer Treatment & Survivorship Facts & Figures 2012-2013. Atlanta, American Cancer Society, 2012.
11. American Cancer Society. Statistics for 2009. http://www.cancer.org/docroot/stt/stt-0.asp (accessed November 25, 2012).
12. Markovic SN, Erickson LA, Rao RD, et al; Melanoma Study Group of the Mayo Clinic Cancer Center: Malignant melanoma in the 21st century. 1. Epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007; 82: 364-380.
13. Albino AP, Reed JA, McNutt NS: Malignant melanoma; in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott-Raven, 1997, pp 1935-1989.
14. Mervic L: Prognostic factors in patients with localized primary cutaneous melanoma. Acta Dermatovenerol Alp Panonica Adriat 2012; 21: 27-31.
15. Uehara S, Kamo R, Harada T, Ishii M: Survival analysis of malignant melanoma in Japan-multivariate analysis of prognostic factors. Osaka City Med J 2009; 55: 35-52.
16. Agarwala SS, Kirkwood JM: Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova) 2000; 10: 230-239.
17. Garbe C, Guenther-Eymann K, Stadler R, Orfanos CE: Adjuvant chemotherapy of malignant melanoma with DTIC: lack of effect in stage I-possible improvement of the prognosis for survival in stage IIb (in German). Hautarzt 1988; 39: 205-212.
18. Barth A, Morton DL: The role of adjuvant therapy in melanoma management. Cancer 1995; 75: 726-734.
19. Pectasides D, Alevizakos N, Bafaloukos D, Tzonou A, Asimakopoulos G, Varthalitis I, Dimitriadis M, Athanassiou A: Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma. Am J Clin Oncol 1994;17: 55-59.
20. Lens M: Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease. Dermatol Ther 2006; 19: 9-18.
21. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
22. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH: High-and lowdose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/ S9111/C9190. J Clin Oncol 2000; 18: 2444-2458.
23. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/ S9512/C509801. J Clin Oncol 2001; 19: 2370-2380.
24. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM Jr, Kugler J, Rodrigue LJ: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13: 2776-2783.
25. Cascinelli N, Bufalino R, Morabito A, Mackie R: Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994; 343: 913-914.
26. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M: Adjuvant interferon in highrisk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22: 53-61.
27. Wheatley K, Ives NJ, Lorigan P: Does adjuvant vaccine therapy really have activity in malignant melanoma? J Clin Oncol 2007; 25: 4693.
28. Mocellin S, Pasquali S, Rossi CR, Nitti D: Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102: 493-501.
29. Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V: Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 2013, DOI: 10.1002/14651858.CD008955.pub2.
30. Petrella T, Verma S, Spithoff K, Quirt I, Mc-Cready D; Melanoma Disease Site Group: Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin Oncol (R Coll Radiol) 2012; 24: 413-423.
31. Shah GD, Chapman PB: Adjuvant therapy of melanoma. Cancer J 2007; 13: 217-222.
32. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
33. Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC Jr, Morton DL, Sondak VK: Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011; 29: 2199-2205.
34. Joosse A, Collette S, Suciu S, Nijsten T, Lejeune F, Kleeberg UR, Coebergh JW, Eggermont AM, de Vries E: Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol 2012; 30: 2240-2247.
35. Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Edwards MJ, Chagpar AB, Martin RC, Stromberg AJ, Hagendoorn L, McMasters KM; Sunbelt Melanoma Trial: Gender-related differences in outcome for melanoma patients. Ann Surg 2006; 243: 693-698.
36. Gogas H, Abali H, Ascierto PA, Demidov L, Pehamberger H, Robert C, Schachter J, Eggermont AM, Hauschild A, Espinosa E: Who benefits most from adjuvant interferon treatment for melanoma? Am J Ther 2013, Epub ahead of print.
37. Uysal-Sonmez O, Tanriverdi O, Esbah O, Uyeturk U, Helvaci K, Bal O, Yalcintas-Arslan U, Budakoglu B, Oksuzoglu B: Multicenter evaluation of patients with cutaneous malignant melanoma in Turkey: MELAS study. Asian Pac J Cancer Prev 2013; 14: 533-537.
38. Barnhill RL, Fine JA, Roush GC, Berwick M: Predicting five-year outcome for patients with cutaneous melanoma in a populationbased study. Cancer 1996; 78: 427-432.
39. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, Mc-Masters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004; 54: 131-149.
40. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
41. Algazi AP, Soon CW, Daud AI: Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res 2010; 2: 197-211.
42. Shashanka R, Smitha BR: Head and neck melanoma. ISRN Surg 2012; 2012: 948302.
43. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, Ding S, Cochran AJ, Eggermont AM, Flaherty KT, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sondak VK: Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 2013; 20: 3961-3968.
44. Malaguarnera L, Ferlito L, Di Mauro S, Im besi RM, Scalia G, Malaguarnera M: Immunosenescence and cancer: a review. Arch Gerontol Geriatr 2001; 32: 77-93.
45. Nomellini V, Gomez CR, Kovacs EJ: Aging and impairment of innate immunity. Contrib Microbiol 2008; 15: 188-205.
46. Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, Gimotty P; AJCC Melanoma Task Force: Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol 2010; 17: 2006-2014.
47. Callender GG, Egger ME, Burton AL, Scoggins CR, Ross MI, Stromberg AJ, Hagendoorn L, Martin RC 2nd, McMasters KM: Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker. Am J Surg 2011; 202: 659-664.
48. Wilson K: High-dose interferon versus GM2 vaccine in high-risk malignant melanoma. J Clin Oncol 2001; 19: 4350.
49. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U; Eastern Cooperative Oncology Group: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10: 1670-1677.
50. Agarwala SS, Lee SJ, Flaherty LE, Smylie M, Kefford RF, Carson WE, Cohen G, Kirkwood M: Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate-and high-risk melanoma (Intergroup trial E 1697) (abstract 8505). J Clin Oncol 2011; 29: 527.
51. Payne MJ, Argyropoulou K, Lorigan P, McAleer JJ, Farrugia D, Davidson N, Kelly C, Chao D, Marshall E, Han C, Wellman S, Middleton MR: Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol 2014; 32: 185-190.
52. Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Sales F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A: Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48: 218-225.
53. McMasters KM, Noyes RD, Reintgen DS, Goydos JS, Beitsch PD, Davidson BS, Sussman JJ, Gershenwald JE, Ross MI; Sunbelt Melanoma Trial: Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 2004; 86: 212-223.
54. McMasters KM, Edwards MJ, Ross MI, Reintgen DS, Martin RC 2nd, Urist MM, Noyes RD, Sussman JJ, Stromberg AJ, Scoggins CR: Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg 2010; 252: 460-465.
55. Wang SQ, Halpern AC: Management of cutaneous melanoma: a public health and individual patient care perspective. Adv Dermatol 2007; 23: 81-98.
56. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE: Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007; 13: 2422-2428.
57. Domingo-Domenech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascon P, Mellado B, Molina R: Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol 2007; 28: 264-272.
58. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20: 3703-3718.
59. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dreno B, Kirkwood JM: Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112: 982-994.
60. Weise AM, Flaherty LE: New options for the adjuvant treatment of cutaneous melanoma? Curr Oncol Rep 2014; 6: 409.